Recent and Upcoming Drug Therapies for Pediatric Heart Failure

Pediatric heart failure (HF) is an important clinical condition with high morbidity, mortality, and costs. Due to the heterogeneity in clinical presentation and etiologies, the development of therapeutic strategies is more challenging in children than adults. Most guidelines recommending drug therap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karla L. Loss, Robert E. Shaddy, Paul F. Kantor
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	pediatric heart failure sacubitril/valsartan ivabradine omecamtiv mecarbil heart failure reduced ejection fraction (HFrEF) Pediatrics RJ1-570
Acceso en línea:	https://doaj.org/article/53b1d27df00c43e6acbd03d5d6a1d915
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53b1d27df00c43e6acbd03d5d6a1d915
record_format	dspace
spelling	oai:doaj.org-article:53b1d27df00c43e6acbd03d5d6a1d9152021-11-11T09:55:09ZRecent and Upcoming Drug Therapies for Pediatric Heart Failure2296-236010.3389/fped.2021.681224https://doaj.org/article/53b1d27df00c43e6acbd03d5d6a1d9152021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fped.2021.681224/fullhttps://doaj.org/toc/2296-2360Pediatric heart failure (HF) is an important clinical condition with high morbidity, mortality, and costs. Due to the heterogeneity in clinical presentation and etiologies, the development of therapeutic strategies is more challenging in children than adults. Most guidelines recommending drug therapy for pediatric HF are extrapolated from studies in adults. Unfortunately, even using all available treatment, progression to cardiac transplantation is common. The development of prospective clinical trials in the pediatric population has significant obstacles, including small sample sizes, slow recruitment rates, challenging endpoints, and high costs. However, progress is being made as evidenced by the recent introduction of ivabradine and of sacubitril/valsartan. In the last 5 years, new drugs have also been developed for HF with reduced ejection fraction (HFrEF) in adults. The use of well-designed prospective clinical trials will be fundamental in the evaluation of safety and efficacy of these new drugs on the pediatric population. The aim of this article is to review the clinical presentation and management of acute and chronic pediatric heart failure, focusing on systolic dysfunction in patients with biventricular circulation and a systemic left ventricle. We discuss the drugs recently approved for children and those emerging, or in use for adults with HFrEF.Karla L. LossRobert E. ShaddyPaul F. KantorFrontiers Media S.A.articlepediatric heart failuresacubitril/valsartanivabradineomecamtiv mecarbilheart failure reduced ejection fraction (HFrEF)PediatricsRJ1-570ENFrontiers in Pediatrics, Vol 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pediatric heart failure sacubitril/valsartan ivabradine omecamtiv mecarbil heart failure reduced ejection fraction (HFrEF) Pediatrics RJ1-570
spellingShingle	pediatric heart failure sacubitril/valsartan ivabradine omecamtiv mecarbil heart failure reduced ejection fraction (HFrEF) Pediatrics RJ1-570 Karla L. Loss Robert E. Shaddy Paul F. Kantor Recent and Upcoming Drug Therapies for Pediatric Heart Failure
description	Pediatric heart failure (HF) is an important clinical condition with high morbidity, mortality, and costs. Due to the heterogeneity in clinical presentation and etiologies, the development of therapeutic strategies is more challenging in children than adults. Most guidelines recommending drug therapy for pediatric HF are extrapolated from studies in adults. Unfortunately, even using all available treatment, progression to cardiac transplantation is common. The development of prospective clinical trials in the pediatric population has significant obstacles, including small sample sizes, slow recruitment rates, challenging endpoints, and high costs. However, progress is being made as evidenced by the recent introduction of ivabradine and of sacubitril/valsartan. In the last 5 years, new drugs have also been developed for HF with reduced ejection fraction (HFrEF) in adults. The use of well-designed prospective clinical trials will be fundamental in the evaluation of safety and efficacy of these new drugs on the pediatric population. The aim of this article is to review the clinical presentation and management of acute and chronic pediatric heart failure, focusing on systolic dysfunction in patients with biventricular circulation and a systemic left ventricle. We discuss the drugs recently approved for children and those emerging, or in use for adults with HFrEF.
format	article
author	Karla L. Loss Robert E. Shaddy Paul F. Kantor
author_facet	Karla L. Loss Robert E. Shaddy Paul F. Kantor
author_sort	Karla L. Loss
title	Recent and Upcoming Drug Therapies for Pediatric Heart Failure
title_short	Recent and Upcoming Drug Therapies for Pediatric Heart Failure
title_full	Recent and Upcoming Drug Therapies for Pediatric Heart Failure
title_fullStr	Recent and Upcoming Drug Therapies for Pediatric Heart Failure
title_full_unstemmed	Recent and Upcoming Drug Therapies for Pediatric Heart Failure
title_sort	recent and upcoming drug therapies for pediatric heart failure
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/53b1d27df00c43e6acbd03d5d6a1d915
work_keys_str_mv	AT karlalloss recentandupcomingdrugtherapiesforpediatricheartfailure AT roberteshaddy recentandupcomingdrugtherapiesforpediatricheartfailure AT paulfkantor recentandupcomingdrugtherapiesforpediatricheartfailure
_version_	1718439214093172736

Recent and Upcoming Drug Therapies for Pediatric Heart Failure

Ejemplares similares